Overview Arimidex in McCune Albright Syndrome Status: Completed Trial end date: 2015-08-01 Target enrollment: Participant gender: Summary The primary objective of this study is to evaluate the safety and efficacy of anastrozole 1 mg given once daily in subjects with McCune-Albright Syndrome. Phase: Phase 2 Details Lead Sponsor: AstraZenecaTreatments: Anastrozole